- Home
- SNDX vs ELVN Comparison
SNDX vs ELVN Comparison
Compare SNDX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- ELVN
- Stock Information
- Founded
- SNDX 2005
- ELVN 2016
- Country
- SNDX United States
- ELVN United States
- Employees
- SNDX N/A
- ELVN N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- SNDX Health Care
- ELVN Health Care
- Exchange
- SNDX Nasdaq
- ELVN Nasdaq
- Market Cap
- SNDX 1.1B
- ELVN 927.8M
- IPO Year
- SNDX 2016
- ELVN 2020
- Fundamental
- Price
- SNDX $9.48
- ELVN $21.30
- Analyst Decision
- SNDX Strong Buy
- ELVN Strong Buy
- Analyst Count
- SNDX 11
- ELVN 5
- Target Price
- SNDX $35.91
- ELVN $39.60
- AVG Volume (30 Days)
- SNDX 1.8M
- ELVN 594.3K
- Earning Date
- SNDX 07-31-2025
- ELVN 08-12-2025
- Dividend Yield
- SNDX N/A
- ELVN N/A
- EPS Growth
- SNDX N/A
- ELVN N/A
- EPS
- SNDX N/A
- ELVN N/A
- Revenue
- SNDX $43,722,000.00
- ELVN N/A
- Revenue This Year
- SNDX $426.77
- ELVN N/A
- Revenue Next Year
- SNDX $98.31
- ELVN N/A
- P/E Ratio
- SNDX N/A
- ELVN N/A
- Revenue Growth
- SNDX N/A
- ELVN N/A
- 52 Week Low
- SNDX $8.58
- ELVN $13.30
- 52 Week High
- SNDX $25.07
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- SNDX 36.85
- ELVN 55.53
- Support Level
- SNDX $11.00
- ELVN $18.53
- Resistance Level
- SNDX $11.83
- ELVN $24.11
- Average True Range (ATR)
- SNDX 0.58
- ELVN 1.96
- MACD
- SNDX -0.11
- ELVN 0.15
- Stochastic Oscillator
- SNDX 10.31
- ELVN 55.68
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.